Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4060-4063
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4060
Targeting methyltransferase-like 5-mediated sphingomyelin metabolism: A novel therapeutic approach in gastric cancer
Jin-Juan Zhang, Chang Yuan, Sheng-Chun Dang
Jin-Juan Zhang, Chang Yuan, Sheng-Chun Dang, Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China
Co-first authors: Jin-Juan Zhang and Chang Yuan.
Author contributions: Zhang JJ, Yuan C, and Dang SC wrote the manuscript; all authors have read and approved the final manuscript.
Supported by Jiangsu Commission of Health, No. LKZ2023012; and Social Development Project of Zhenjiang City, No. SS2023011.
Conflict-of-interest statement: All the authors have no relevant conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sheng-Chun Dang, Doctor, Professor, Surgeon, Department of General Surgery, The Affiliated Hospital of Jiangsu University, No. 438 Jiefang Road, Zhenjiang 212001, Jiangsu Province, China. dscgu@163.com
Received: April 5, 2024
Revised: May 17, 2024
Accepted: June 5, 2024
Published online: October 15, 2024
Processing time: 174 Days and 5.6 Hours
Core Tip

Core Tip: This study comprehensively analyzes the role of methyltransferase-like 5 (METTL5) in the progression of gastric cancer (GC), highlighting its potential as a new therapeutic target and prognostic biomarker. However, further research is needed to fully understand the functional mechanism of METTL5 in GC and translate these insights into clinical applications. Targeting METTL5-mediated sphingomyelin metabolism is a novel therapeutic approach in GC.